Joseph J. Kash

1.3k total citations · 2 hit papers
10 papers, 976 citations indexed

About

Joseph J. Kash is a scholar working on Surgery, Genetics and Reproductive Medicine. According to data from OpenAlex, Joseph J. Kash has authored 10 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Surgery, 3 papers in Genetics and 3 papers in Reproductive Medicine. Recurrent topics in Joseph J. Kash's work include BRCA gene mutations in cancer (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Breast Cancer Treatment Studies (2 papers). Joseph J. Kash is often cited by papers focused on BRCA gene mutations in cancer (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Breast Cancer Treatment Studies (2 papers). Joseph J. Kash collaborates with scholars based in United States and Belgium. Joseph J. Kash's co-authors include William A. Cliby, Ritu Salani, Don S. Dizon, Alexi A. Wright, Alexander Olawaiye, Kathleen N. Moore, Robert L. Coleman, Michael A. Bookman, Kari Bohlke and Deborah K. Armstrong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Joseph J. Kash

10 papers receiving 967 citations

Hit Papers

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ov... 2016 2026 2019 2022 2016 2016 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
    2016 295 citations Alexi A. Wright, Kari Bohlke et al. Journal of Clinical Oncology profile →
  2. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
    2016 274 citations Alexi A. Wright, Kari Bohlke et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph J. Kash United States 9 485 324 275 269 230 10 976
Hans-Joachim Lueck Germany 14 287 0.6× 207 0.6× 532 1.9× 276 1.0× 144 0.6× 37 917
Saverio Danese Italy 16 266 0.5× 213 0.7× 408 1.5× 199 0.7× 102 0.4× 31 880
M. Gropp Germany 10 570 1.2× 346 1.1× 232 0.8× 80 0.3× 232 1.0× 23 766
Kari L. Ring United States 20 406 0.8× 155 0.5× 500 1.8× 302 1.1× 467 2.0× 74 1.3k
C. Tropé Norway 9 947 2.0× 492 1.5× 391 1.4× 105 0.4× 392 1.7× 13 1.2k
David T. Bollag France 7 1.1k 2.3× 337 1.0× 646 2.3× 135 0.5× 205 0.9× 11 1.4k
Antonio De Leo Italy 17 170 0.4× 164 0.5× 228 0.8× 155 0.6× 197 0.9× 101 869
James J. Burke United States 17 674 1.4× 267 0.8× 242 0.9× 133 0.5× 984 4.3× 27 1.6k
Albert Steren United States 13 339 0.7× 184 0.6× 259 0.9× 71 0.3× 259 1.1× 21 726
Anne‐Claire Hardy‐Bessard France 16 236 0.5× 125 0.4× 640 2.3× 230 0.9× 129 0.6× 59 961

Countries citing papers authored by Joseph J. Kash

Since Specialization
Citations

This map shows the geographic impact of Joseph J. Kash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph J. Kash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph J. Kash more than expected).

Fields of papers citing papers by Joseph J. Kash

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph J. Kash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph J. Kash. The network helps show where Joseph J. Kash may publish in the future.

Co-authorship network of co-authors of Joseph J. Kash

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph J. Kash. A scholar is included among the top collaborators of Joseph J. Kash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph J. Kash. Joseph J. Kash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al.. (2016). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Obstetrical & Gynecological Survey. 71(12). 717–718. 19 indexed citations
2.
Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al.. (2016). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 34(28). 3460–3473. 295 indexed citations breakdown →
3.
Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al.. (2016). Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecologic Oncology. 143(1). 3–15. 274 indexed citations breakdown →
4.
Livingston, Robert B., William E. Barlow, Joseph J. Kash, et al.. (2011). SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment. 130(1). 123–131. 4 indexed citations
5.
Lo, Shelly S., Patricia Mumby, John D. Norton, et al.. (2010). Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection. Journal of Clinical Oncology. 28(10). 1671–1676. 231 indexed citations
6.
7.
Treon, Steven P., Jacob D. Soumerai, Andrew R. Branagan, et al.. (2008). Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Research. 15(1). 355–360. 89 indexed citations
8.
Norton, John D., Patricia Mumby, Jeffrey B. Smerage, et al.. (2007). Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. Journal of Clinical Oncology. 25(18_suppl). 577–577. 15 indexed citations
9.
Voelzke, Bryan B., Kyoko Sakamoto, Alexander Hantel, et al.. (2002). Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. Urology. 60(2). 218–222. 16 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans-Joachim Lueck Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by M. Gropp Breakdown of academic impact, for papers by Kari L. Ring Breakdown of academic impact, for papers by C. Tropé Breakdown of academic impact, for papers by David T. Bollag Breakdown of academic impact, for papers by Antonio De Leo Breakdown of academic impact, for papers by James J. Burke Breakdown of academic impact, for papers by Albert Steren Breakdown of academic impact, for papers by Anne‐Claire Hardy‐Bessard
Rankless by CCL
2026